InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.011

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 WHO Selects Proposed INN for Cymerus MSCs 29 May 2026 8:56AM $0.255 $0.011 fallen by 95.69%
$3 Expected Timing of Clinical Trial Results 27 May 2026 8:54AM $0.260 $0.011 fallen by 95.77%
$3 Cleansing Notice 8 May 2026 9:01AM $0.315 $0.011 fallen by 96.51%
$3 Application for quotation of securities - CYP 8 May 2026 8:57AM $0.315 $0.011 fallen by 96.51%
$3 Proposed issue of securities - CYP 4 May 2026 9:05AM $0.323 $0.011 fallen by 96.59%
$3 Cynata Secures Commitments for $1.5m Placement 4 May 2026 9:05AM $0.323 $0.011 fallen by 96.59%
$3 March 2026 Quarterly Activity Report & Appendix 4C 30 Apr 2026 10:00AM $0.323 $0.011 fallen by 96.59%
$3 Trading Halt 30 Apr 2026 9:03AM $0.323 $0.011 fallen by 96.59%
$3 Notification of cessation of securities - CYP 7 Apr 2026 8:31AM $0.295 $0.011 fallen by 96.27%
$3 Last Visit in GvHD Trial Completed 30 Mar 2026 8:58AM $0.300 $0.011 fallen by 96.33%
$3 Appendix 4D & Half-Year Financial Statements 26 Feb 2026 3:43PM $0.360 $0.011 fallen by 96.94%
$3 Cynata to Present at 2026 Euroz Hartleys Healthcare Forum 5 Feb 2026 9:29AM $0.350 $0.011 fallen by 96.86%
$3 Investor Webinar 4 Feb 2026 9:05AM $0.335 $0.011 fallen by 96.72%
$3 December 2025 Quarterly Activity Report and Appendix 4C 29 Jan 2026 9:30AM $0.345 $0.011 fallen by 96.81%
$3 Cynata Completes $1.2m At-The-Market Raise 23 Jan 2026 5:41PM $0.315 $0.011 fallen by 96.51%
$3 Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial 15 Dec 2025 9:09AM $0.265 $0.011 fallen by 95.85%
$3 Positive DSMB Review in Phase 1/2 Kidney Transplant Trial 4 Dec 2025 8:56AM $0.250 $0.011 fallen by 95.60%
$3 Appendix 3Y - Dr Paul Wotton 1 Dec 2025 8:48AM $0.285 $0.011 fallen by 96.14%
$3 Appendix 3Y - Dr Darryl Maher 1 Dec 2025 8:46AM $0.285 $0.011 fallen by 96.14%
$3 Appendix 3Y - Dr Geoff Brooke 1 Dec 2025 8:45AM $0.285 $0.011 fallen by 96.14%
$3 Notification of cessation of securities - CYP 1 Dec 2025 8:39AM $0.285 $0.011 fallen by 96.14%
$3 Final Patient Visit Complete in Phase 3 Osteoarthritis Trial 24 Nov 2025 9:24AM $0.255 $0.011 fallen by 95.69%
$3 Investor Presentation 17 Nov 2025 8:53AM $0.245 $0.011 fallen by 95.51%
$3 Results of Annual General Meeting 13 Nov 2025 11:37AM $0.250 $0.011 fallen by 95.60%
$3 AGM Presentations 13 Nov 2025 8:22AM $0.250 $0.011 fallen by 95.60%

26 - 50 of 709 results

Page 2 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.